Request Discount

Metabolic Disorders Therapeutics Market (disease Type - Diabetes, Obesity, Hypercholesterolemia, and Lysosomal Storage Disease; Product - Metachromatic Leukodystrophy, Globoid Leukodystrophy, Hepatic Encephalopathy, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2028

  • Published : May, 2022

  • Rep Id : HC0054

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on the metabolic disorders therapeutics market provides an in-depth analysis of segments and sub-segments in the global as well as regional metabolic disorders therapeutics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional metabolic disorders therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecasts, and dollar values of the global metabolic disorders therapeutics market. According to the report, the global metabolic disorders therapeutics market is projected to grow at a CAGR of 7% over the forecast period of 2022-2028.

 

Market Insight

The value of the metabolic disorders therapeutics market was over 70 billion in 2022 and is expected to reach USD 108 billion in 2028. Metabolism is a process in which the human body generates energy from the food humans eat. The food that humans consume comprises proteins, carbohydrates, and fats. Chemicals in the human digestive system break the food parts down into sugars and acids. Metabolic disorders occur when abnormal chemical reactions in the human body disturb this process. This is due to enzyme deficiency: as all processes in the body are controlled by enzymes. Any disturbance in the pathways involved in the development and metabolism of carbohydrates, proteins, and fats, leads to metabolic disorder.

 

An increase in academia-industry collaborations for drug developments is the key factor responsible for the growth of the metabolic disorders therapeutics market. Furthermore, the growing diabetic population is significantly contributing to the growth of this market. As per International Agency for Research on Cancer, there were 19.3 million new cancer cases worldwide in 2020, and the World Health Organization estimates that there will be 422 million diabetic individuals worldwide (WHO). Low compliance, the adherence rate for metabolic disorder therapies, and the availability of alternative treatment options are the major challenges faced by the players operating in this market. The global metabolic disorders therapeutics market is anticipated to present several opportunities for growth of market size over the forecast period due to strategic collaborations and acquisitions and increased R & D investment.

 

North America is expected to be the largest region in the market and Asia-Pacific is expected to be the fastest growing region. The diabetic population in North America is growing significantly, especially in countries such as the United States. Apart from these, the number of people suffering from obesity is also growing due to a sedentary lifestyle. People suffering from diabetes and obesity are more prone to metabolic disorders. Therefore, demand for the therapeutics for metabolic disorders is expected to remain high. Furthermore, the high concentration of market players is also aiding the growth of the market in North America. Companies such as Merck, Eli Lily, and others are based in the North American region. Asia-Pacific is expected to be the fastest growing region due to the high prevalence of diabetes and obesity in countries such as India and China and also due to improving healthcare infrastructure in the region.


Metabolic Disorders Therapeutics Market

 

Segment Covered

The report on the global metabolic disorders therapeutics market covers segments such as disease type, and product. On the basis of disease type, the sub-markets include diabetes, obesity, hypercholesterolemia, and lysosomal storage disease. On the basis of product, the sub-markets include metachromatic leukodystrophy, globoid leukodystrophy, hepatic encephalopathy, and others.

 

Companies Profiled:

The report provides profiles of the companies in the market such as AstraZeneca Plc, Novo Nordisk, Sanofi, Merck, Eli Lily, Abbvie, Actelion Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals, and Biocon.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors driving and restraining this market's growth. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the metabolic disorders therapeutics market. Moreover, the study highlights current market trends and provides forecasts for 2022-2028. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount